FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W967514293> ?p ?o ?g. }

• W967514293 endingPage "100" @default.
• W967514293 startingPage "93" @default.
• W967514293 abstract "The free beta-subunit of human chorionic gonadotrophin (hCGbeta) is well established as an ectopic product of epithelial tumors. Originally explained as an epi-phenomenon, hCGbeta production by many types of carcinoma is increasingly regarded as a significant tumor event. Studies in bladder cancer have shown that hCGbeta production, while not diagnostic, is a very good indicator for poor prognosis through correlations with resistance to radiotherapy and rapid metastasis. These clinical findings led to in vitro studies that have shown a direct response to hCGbeta by bladder carcinoma cell lines. This response is linked by inhibition of apoptosis to an increase in cell population. More recently, studies on hCGbeta as a marker for poor prognosis in other epithelial cancers now suggest that this phenomenon may not be restricted to bladder carcinoma. Thus, ectopic hCGbeta represents an ideal target for immunodepletive therapy. Antisera were generated from mice vaccinated with full-length hCGbeta carboxy terminal peptide (CTP37) and a truncated region comprising 24 of the amino acids of the CTP (CTP24), expressed on the surface of cowpea mosaic virus (CPMV). The effect of the resultant murine antiseras on bladder carcinoma cell growth in vitro was investigated. When CTP37 antisera, at dilutions of 1:50 and 1:100, were incubated with two hCGbeta-producing cell lines, SCaBER and RT112, significant reductions in cell number, up to 43%, were observed. In the bladder cancer cell line T24, which does not produce hCGbeta, CTP37 antisera had no growth effects. CTP24 antiserum, like control sera from mice immunized with wild-type CPMV, had no effects on the in vitro growth of any cell lines. This implies that full-length CTP37, but not CTP24, is involved in the oncogenic inhibition of apoptosis by hCGbeta. hCGbeta CTP37 vaccines are available as well-tested antifertility vaccines in the Third World. They have now been tested on cancer patients. This study is the only in vitro evidence that such a vaccine would have beneficial antitumor effects via immunodepletion mechanisms. We propose that vaccines such as this could be used as an adjuvant therapy in the treatment of hCGbeta-producing bladder cancers." @default.
• W967514293 created "2016-06-24" @default.
• W967514293 creator A5018729838 @default.
• W967514293 creator A5062051160 @default.
• W967514293 creator A5087594592 @default.
• W967514293 date "2003-01-01" @default.
• W967514293 modified "2023-09-29" @default.
• W967514293 title "Reduction of Bladder Cancer Cell Growth in Response to hCGβ CTP37 Vaccinated Mouse Serum" @default.
• W967514293 cites W2031192188 @default.
• W967514293 cites W2594352862 @default.
• W967514293 doi "https://doi.org/10.3727/000000003108748649" @default.
• W967514293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14649543" @default.
• W967514293 hasPublicationYear "2003" @default.
• W967514293 type Work @default.
• W967514293 sameAs 967514293 @default.
• W967514293 citedByCount "23" @default.
• W967514293 countsByYear W9675142932012 @default.
• W967514293 countsByYear W9675142932013 @default.
• W967514293 countsByYear W9675142932014 @default.
• W967514293 countsByYear W9675142932015 @default.
• W967514293 countsByYear W9675142932017 @default.
• W967514293 countsByYear W9675142932022 @default.
• W967514293 countsByYear W9675142932023 @default.
• W967514293 crossrefType "journal-article" @default.
• W967514293 hasAuthorship W967514293A5018729838 @default.
• W967514293 hasAuthorship W967514293A5062051160 @default.
• W967514293 hasAuthorship W967514293A5087594592 @default.
• W967514293 hasConcept C121608353 @default.
• W967514293 hasConcept C126322002 @default.
• W967514293 hasConcept C134018914 @default.
• W967514293 hasConcept C2779013556 @default.
• W967514293 hasConcept C502942594 @default.
• W967514293 hasConcept C54355233 @default.
• W967514293 hasConcept C55493867 @default.
• W967514293 hasConcept C62112901 @default.
• W967514293 hasConcept C71924100 @default.
• W967514293 hasConcept C81885089 @default.
• W967514293 hasConcept C86803240 @default.
• W967514293 hasConcept C97037327 @default.
• W967514293 hasConceptScore W967514293C121608353 @default.
• W967514293 hasConceptScore W967514293C126322002 @default.
• W967514293 hasConceptScore W967514293C134018914 @default.
• W967514293 hasConceptScore W967514293C2779013556 @default.
• W967514293 hasConceptScore W967514293C502942594 @default.
• W967514293 hasConceptScore W967514293C54355233 @default.
• W967514293 hasConceptScore W967514293C55493867 @default.
• W967514293 hasConceptScore W967514293C62112901 @default.
• W967514293 hasConceptScore W967514293C71924100 @default.
• W967514293 hasConceptScore W967514293C81885089 @default.
• W967514293 hasConceptScore W967514293C86803240 @default.
• W967514293 hasConceptScore W967514293C97037327 @default.
• W967514293 hasIssue "2" @default.
• W967514293 hasLocation W9675142931 @default.
• W967514293 hasLocation W9675142932 @default.
• W967514293 hasOpenAccess W967514293 @default.
• W967514293 hasPrimaryLocation W9675142931 @default.
• W967514293 hasRelatedWork W1499339123 @default.
• W967514293 hasRelatedWork W1993375705 @default.
• W967514293 hasRelatedWork W2059361584 @default.
• W967514293 hasRelatedWork W2085652928 @default.
• W967514293 hasRelatedWork W2130497075 @default.
• W967514293 hasRelatedWork W2142257207 @default.
• W967514293 hasRelatedWork W2772819648 @default.
• W967514293 hasRelatedWork W2913594760 @default.
• W967514293 hasRelatedWork W3034722890 @default.
• W967514293 hasRelatedWork W3173207637 @default.
• W967514293 hasVolume "14" @default.
• W967514293 isParatext "false" @default.
• W967514293 isRetracted "false" @default.
• W967514293 magId "967514293" @default.
• W967514293 workType "article" @default.